Yang Xiaoming: The annual production capacity of inactivated vaccines in Wuhan and Beijing will exceed 3 billion doses

Jimu news reporter Chen Qian

Yang Xiaoming, chairman of Sinopharm China Biotechnology Co., Ltd., said at the health sub-forum of the Shanghai Cooperation Organization Non-Governmental Friendship Forum on June 2 that the annual production capacity of Sinopharm's Wuhan and Beijing Biological Institutes will exceed 3 billion doses after the expansion of the two major vaccine production bases, of which the Wuhan Institute of Biology will reach an annual production capacity of 1 billion doses after expansion.

Yang Xiaoming said that when developing a new crown vaccine, Sinopharm regards inactivated vaccines as the first choice. This was not only the urgent need of the epidemic at that time, but also because the technical platform of inactivated vaccines was reliable and had the advantage of large-scale production. With the support of the state, the inactivated vaccine for new crown pneumonia developed by the Wuhan Institute of Biology took only 98 days from the start of research and development to the approval of clinical trials, which can be called "wartime speed". In general, from the virus to the vaccine, the international adoption time may take 8 to 10 years. Although it has created a miracle in speed, in the process of research and development, the adherence to standards is not lowered, the process is not reduced, and the effect of China's vaccine has also been recognized by WHO and many countries.

Yang Xiaoming said that from the perspective of use, Chinese vaccines can effectively protect British and South African disease strains, and also have good protection for Indian disease strains. At present, The Wuhan Institute of Biology has just completed the expansion work, with a design annual production capacity of 1 billion doses, and the Beijing Institute of Biology is also making every effort to expand its production capacity, and it is expected that the total annual production capacity will exceed 3 billion doses. China's vaccines have been approved for marketing in 6 countries and approved for use in 69 countries, playing an increasingly important role in the world's epidemic prevention work.

For more exciting information, please download the "Jimu News" client in the app market, welcome to provide news leads, and pay as soon as you adopt them. 24-hour reporting hotline [phone].